PF-Atlas › Clinical Trials › NCT03832946

A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis

GB0139 · Phase 2

Registry ID
NCT03832946
Phase
Phase 2
Status
Completed
Drug / intervention
GB0139
Sponsor
Galecto Biotech AB
Start
2019-02-19
Enrollment
172
Locations
128

About this trial

This is a randomized, double-blind, placebo-controlled phase 2b trial in subjects with IPF (idiopathic pulmonary fibrosis) investigating the efficacy and safety of GB0139.

View NCT03832946 on ClinicalTrials.gov →

Explore related

Galectin-3 Inhibition — Treatment profileAll GB0139 trialsAll IPF trials

Related trials

GB0139 — NCT-GB0139
Medical disclaimer. This page summarizes public trial data for NCT03832946 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.